Responsibility to Our Customers
Examples of Initiatives
Initiative for Access to Healthcare
Sumitomo Chemical started its pharmaceuticals business as the first Japanese company to manufacture synthetic pharmaceuticals
based on its advanced organic synthesis technology. Our Group company Sumitomo Pharma Co., Ltd. considers the below listed
items to be part of its duty to its customers in the pharmaceutical business.
Fair Marketing(Refer to section “12. Cooperation with Healthcare Professionals, etc.,” “13. Sales, Marketing and Information Communication
Activities” of Sumitomo Pharma’s Compliance Standard for more details.)
https://www.sumitomo-pharma.com/profile/compliance_risk-management/compliance/● Transparency in Partnerships with Patient Groups and Medical Institutions

As a member of the Japan Pharmaceutical Manufacturers Association (JPMA) which issued its Transparency Guideline for theRelation between Corporate Activities and Medical Institutions and its Transparency Guideline for the Relation between CorporateActivities and Patients’ Groups, Sumitomo Pharma established its own Guidelines for Transparency in Partnerships with MedicalInstitutions in October 2011 and Guidelines for Transparency in Partnerships with Patients’ Groups in April 2013. In accordancewith these guidelines, the company publicly discloses information on its corporate website on such issues as payments that thecompany makes to medical institutions, healthcare professionals, patient groups and patient advocacy groups.
● Our Approach to Promotional Activities for Healthcare Professionals

In compliance with the IFPMA Code of Practice, the JPMA Code of Practice, and Guidelines for Prescription Drug Marketing
Information Provision issued by the Ministry of Health, Labour and Welfare, Sumitomo Pharma has drawn up the “Rules forMarketing Information Provision” and established the Department Responsible for Supervising Marketing Information Provision.
The Department Responsible for Supervising Marketing Information Provision supervises and provides guidance to departmentsthat implement detailing activities, examines and approves materials, carries out monitoring as well as education and training for
officers and employees, operates a complaints desk and handles complaints.
As an advisory body to the Department Responsible for Supervising Marketing Information Provision, we have established
the Review and Supervisory Committee, which is held regularly. It has an external chairperson who is completely independentof our company.
Sumitomo Pharma has drawn up internal rules for the examination of materials for use in promotional activities titled “Rulesfor Examination of Materials Used in Marketing Information Provision” and created an internal structure for examination andapproval of such materials.
https://www.sumitomo-pharma.com/sustainability/healthcare_innovation/fair_marketing.html

Contribution to Global Health● Countermeasures to Antimicrobial Resistance (AMR) and Initiatives for the Appropriate Use of Antibiotics
Sumitomo Pharma is conducting joint research with a drug discovery group of Kitasato Institute.
In 2019, as a partnership initiative with the Ministry of Health of Vietnam, Sumitomo Pharma and the National Center for Global
Health and Medicine jointly commenced the first antibiotic susceptibility surveillance study in Vietnam in order to contribute toantimicrobial resistance (AMR) countermeasures and promote the proper use of antibiotics in Vietnam. In 2020, we completed
a data analysis of the first year of research, reports of results to each hospital facility, and exchanges of opinions. In 2021, wepresented this content at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID). The second antibiotic
susceptibility surveillance study began in February 2023.
● Efforts for the Eradication of Malaria

Sumitomo Pharma is working on the research and development of malaria vaccines in collaboration with Ehime University andthe global organization PATH, and supports initiatives for the eradication of malaria in several countries in Asia and Africa. The
Company has cooperated with NPOs, local governments and communities to provide insecticide-treated mosquito nets, rapid
diagnostic test kits for malaria, and educational activities in Zambia, Tanzania, and Indonesia, as well as advocacy initiatives forpublic awareness of malaria in Japan.

1Responsibility to Our Customers● Participation in the Global Health Innovative Technology Fund (GHIT Fund)

Through participation in the GHIT Fund, Sumitomo Pharma seeks to improve access to medicines by exploring the possibility ofutilizing our innovative drug discovery technologies to tackle neglected tropical diseases (NTDs), malaria, and other diseases withsignificant unmet medical needs.
https://www.sumitomo-pharma.com/sustainability/social/contribution_to_global_health.html

Initiatives to Improve Access to Medicines● Targets and KPIs for Material Issues
As described below, Sumitomo Pharma established the targets and KPIs for initiatives to improve access to medicines andadvocacy, which is a material issue linked to value creation.
Material Issues

Improving access tomedicines and advocacy

Targets

KPIs

Targets of KPIs

Attempt to improve access to medicines
by promoting disease awareness frompatient-centered perspectives, which is
expected to reduce illness stigma andfacilitate early treatment, and by working
to lessen a drug lag, which will increase
treatment options for patients.
Contribute to the betterment of thehealthcare system in countries/regions thatstruggle with equal access to necessary
healthcare, by developing healthcare professionals, raising awareness of the public,and making policy recommendations
through collaboration with the industry,
governments, and NPOs/NGOs

1. Further increase in health literacyof the public, including patients•N umber of public lecture participants by
FY2027 cumulative total of 10,000 since FY2023*• Total annual visits to schizophrenia and bipolar
disorder disease awareness website (KokoroShare) 40% increase over FY2022 by FY2027*

2. Number of products, and policy
recommendations contributing
to access to medicines• Responding to requests for developmentof unapproved and off-label drugs of highmedical necessity*• Continued participation in policy
recommendations*

3. Number of partnerships
contributing to improvement inhealthcare access in developingcountries• Constantly two or more

* Targets of KPI for Sumitomo Pharma non-consolidated

https://www.sumitomo-pharma.com/sustainability/assets/pdf/material_issues_kpi_en.pdf● Partnership Initiative “Access Accelerated”

Sumitomo Pharma has participated in a partnership initiative called “Access Accelerated” since its launch in 2017. AccessAccelerated is a coalition of more than 20 pharmaceutical companies and six international institutions, including the World Bank.
In fiscal 2021, a total of 121 individual access programs were implemented by different companies in 126 low- to middle-income
countries in Africa and Asia, while programs on pharmaceutical regulatory easing, healthcare specialist development, and public
education for citizen awareness were promoted centering on three target countries: Kenya, Ghana, and Vietnam.
● Initiatives to Fight against Counterfeit Pharmaceuticals

As a member of the Pharmaceutical Security Institute (PSI), the Company maintains close contact with other global pharmaceutical manufacturers in information gathering and promoting anti-counterfeit enforcement operations. Sumitomo Pharma donatedto the International Criminal Police Organization (INTERPOL) a total of 4.5 million Euro over a three-year period beginning in 2013.
The donation was used to fund activities to promote public awareness of counterfeit pharmaceuticals and efforts to prevent
pharmaceutical crime as well as for the training of specialist pharmaceutical crime investigators.
https://www.sumitomo-pharma.com/sustainability/social/improvel_access.html

Looking Ahead
Collecting information through close consultation with internal and external partners, and maintaining a proactive attitude when
listening to our customers’ opinions, Sumitomo Chemical remains committed to continuously providing products that satisfy theneeds of its customers. Moreover, the Company is expanding information disclosure in order to provide our customers with vital
information in the most appropriate manner.

2